| Brand names |
Trileptal®, others in various regions |
| Form |
Oral tablet (usually 100 mg, 300 mg, 600 mg, or 1,200 mg) |
| Class |
Second‑generation antiepileptic (antiepileptic drug, AED) |
| Mechanism of action |
Enhances the slow inactivation of voltage‑gated sodium channels, stabilizing hyperexcitable neuronal membranes. |
| Common uses |
• Partial‑onset (focal) seizures (including complex partial seizures)
• Adjunctive therapy for epilepsy
• Certain forms of neuropathic pain (off‑label use in some regions) |
| Typical starting dose |
150 mg twice daily (300 mg total) – can be increased gradually |
| Maintenance dose |
300–600 mg twice daily (600–1,200 mg total). The dose is titrated up over weeks, with a max of ~1,200 mg twice daily for some patients. |
| Loading dose (optional) |
600 mg (300 mg BID) on day 1, then titration. |
| Route |
Oral, take with or without food. |
| Half‑life |
~9–11 h (active metabolite 10,11‑epoxy‑oxcarbazepine). |
| Key side‑effects |
• Dizziness, somnolence, ataxia, nausea
• Hyponatremia (low sodium – watch for fatigue, headache, confusion)
• Rash (rare but potentially serious – Stevens‑Johnson syndrome)
• Headache, fatigue, blurred vision |
| Common drug interactions |
• Other sodium‑channel blockers (e.g., carbamazepine, phenytoin) – additive CNS depression
• CYP3A4 inducers (rifampin, carbamazepine, phenytoin, phenobarbital) – ↓oxcarbazepine levels
• Hormonal contraceptives – may reduce effectiveness (though less than carbamazepine)
• Alcohol – additive CNS depression |
| Contraindications |
• Severe hyponatremia
• Known hypersensitivity to oxcarbazepine or any excipients
• Serious liver disease (may alter metabolism) |
| Special populations |
• Pregnancy – Category C; use only if benefits outweigh risks. Avoid in the first trimester if possible.
• Breastfeeding – minimal data; generally considered compatible but consult a clinician.
• Elderly – start low and go slow; higher risk of dizziness and falls.
• Renal impairment – dose adjustment may be needed; monitor serum levels if possible. |
| Monitoring recommendations |
• Baseline serum sodium; repeat after 2–4 weeks if symptomatic or in high‑risk patients.
• Monitor for rash; if any rash appears, discontinue immediately.
• Check liver function tests if hepatic disease or at long‑term use. |
| Patient counseling points |
• Take consistently: Even if you feel fine, missing doses can lead to breakthrough seizures.
• Do not stop abruptly: Gradual tapering is essential to prevent withdrawal seizures or rebound seizures.
• Watch for dizziness: If you feel dizzy or light‑headed, avoid driving or operating heavy machinery until you know how the drug affects you.
• Keep your sodium intake adequate: Low sodium diets may increase the risk of hyponatremia.
• Report rash: Any rash, especially if it spreads or is painful, should be evaluated immediately. |
| Commonly asked questions |
Q: Can I take it with other anticonvulsants? A: Yes, but dosages may need adjustment, and watch for cumulative CNS depression.
Q: Is it safe for long‑term use? A: Long‑term use is common and generally well tolerated, but periodic monitoring of sodium and liver enzymes is recommended.
Q: Will it cause weight gain? A: Weight gain is uncommon; weight loss is more typical due to appetite suppression in some patients.
Q: Can I take it with alcohol? A: Alcohol may worsen drowsiness and dizziness; limit consumption. |